Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.

After 12 weeks of treatment, Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores were 5.8 points higher for patients randomized to the SGLT2 inhibitor over placebo (P=0.001), bringing scores from the low 60s at baseline to the high 60s, reported Mikhail Kosiborod, MD, of Saint Luke's Mid America Heart Institute in Kansas City, Missouri.

"The treatment effect was large, clinically meaningful, and statistically significant," Kosiborod concluded of the 324-person study during a late-breaking trial session at the Heart Failure Society of America (HFSA) meeting held both virtually and in Denver. He mentioned that the study manuscript is in press at Nature Medicine.

Read the rest of the Medpage Today article: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients